| SESN3 | 143686 | 17504987 | - | - | - | - | - | Endometrioid (n=361) and non-endometrioid uterine cancers (n=23) | - | 63.9 | - | "IA (n=62); IB/IC (n=203); II (n=26) | III (n=50); IV (n=13)" | | "[1] The 5' CpG islands for SESN3 and TITF1 are novel cancer-specific methylation markers. Methylation at these loci is strongly associated with aberrant MLH1 methylation in endometrial cancers. [2] DMH and COBRA identified two CpG islands methylated in tumors but not in normal DNAs: SESN3 (PY2B4) and TITF1 (SC77F6/154). Bisulfite sequencing showed dense methylation of the CpG islands and confirmed the COBRA assays. SESN3 and TITF1 were methylated in 20% and 70% of endometrioid tumors | respectively. MLH1 methylation was seen in 28% of the tumors. TITF1 and SESN3 methylation was highly associated with MLH1 methylation (P<0.0001). SESN3 and TITF1 were methylated in endometrioid and non-endometrioid tumors | whereas MLH1 methylation was restricted to endometrioid tumors. Methylation at these markers was not associated with survival outcomes." | 0 |